Evidence map›Paper›PMID 34817269›Full record

ArticleAmerican journal of physiology. Cell physiology2022

Glucose consumption of vascular cell types in culture: toward optimization of experimental conditions.

Keiichi Torimoto, Keisuke Okuno, Ryohei Kuroda, No'Ad Shanas, Stephanie M Cicalese, Kunie Eguchi, Katherine J Elliott, Tatsuo Kawai, Cali B Corbett, Amanda M Peluzzo and 6 more

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Mitochondrial fission inhibition protects against hypertension induced by angiotensin II.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Keiichi TorimotoCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Keisuke OkunoCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Ryohei KurodaCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
No'Ad ShanasCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Stephanie M CicaleseCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.ORCID 0000-0003-1688-5053
Kunie EguchiCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Katherine J ElliottCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Tatsuo KawaiCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Cali B CorbettCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Amanda M PeluzzoCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Amanda K St PaulCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Michael V AutieriCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Rosario ScaliaCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Victor RizzoCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Tomoki HashimotoBarrow Aneurysm and AVM Research Center, Departments of Neurosurgery and Neurobiology, Barrow Neurological Institute, Phoenix, Arizona.
Satoru EguchiCardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.ORCID 0000-0002-8407-7501
Temple University · USBarrow Neurological Institute · US

Funding

miRNA-mediated reduction of VSMC foam cell formationR01HL117724 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI AUTIERI, MICHAEL V · 2013 to 2022
$3.8M
Inflammatory Responses of The Visceral Adipose Tissue MicrocirculationR01DK111042 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI EGUCHI, SATORU, SCALIA, ROSARIO G · 2017 to 2020
$2.3M
EGF-ADAM17 axis in the pathophysiology of intracranial aneurysmR01NS109382 · NINDS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI EGUCHI, SATORU, HASHIMOTO, TOMOKI · 2019 to 2023
$2.2M
Mechanisms for intracranial aneurysm ruptureR01NS109584 · NINDS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI HASHIMOTO, TOMOKI · 2020 to 2024
$1.9M
Mechanism of Hypertensive Vascular Remodeling and End-Organ DamageR01HL133248 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI EGUCHI, SATORU · 2016 to 2019
$1.8M
Vascular signal as a therapeutic target for abdominal aortic aneurysmR01HL128324 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI EGUCHI, SATORU, RIZZO, VICTOR J. · 2015 to 2018
$1.6M
NHLBI NIH HHS R01 HL117724NHLBI NIH HHS R01 HL128324NHLBI NIH HHS R01 HL133248NIDDK NIH HHS R01 DK111042NINDS NIH HHS R01 NS109382NINDS NIH HHS R01 NS109584
6 · The paper itself

Abstract

In this study, we have looked for an optimum media glucose concentration and compared glucose consumption in three vascular cell types, endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and adventitial fibroblasts (AFs) with or without angiotensin II (AngII) stimulation. In a subconfluent 6-well experiment in 1 mL DMEM with a standard low (100 mg/dL), a standard high (450 mg/dL), or a mixed middle (275 mg/dL) glucose concentration, steady and significant glucose consumption was observed in all cell types. After 48-h incubation, media that contained low glucose was reduced to almost 0 mg/dL, media that contained high glucose remained significantly higher at ∼275 mg/dL, and media that contained middle glucose remained closer to physiological range. AngII treatment enhanced glucose consumption in AFs and VSMCs but not in ECs. Enhanced extracellular acidification rate by AngII was also observed in AFs. In AFs, AngII induction of target proteins at 48 h varied depending on the glucose concentration used. In low glucose media, induction of glucose regulatory protein 78 or hexokinase II was highest, whereas induction of VCAM-1 was lowest. Utilization of specific inhibitors further suggests essential roles of angiotensin II type-1 receptor and glycolysis in AngII-induced fibroblast activation. Overall, this study demonstrates a high risk of hypo- or hyperglycemic conditions when standard low or high glucose media is used with vascular cells. Moreover, these conditions may significantly alter experimental outcomes. Media glucose concentration should be monitored during any culture experiments and utilization of middle glucose media is recommended for all vascular cell types.

Indexed as

AnimalsAorta, ThoracicCells, CulturedDose-Response Relationship, DrugEndothelial CellsGlucoseHumansMaleMuscle, Smooth, VascularMyocytes, Smooth MuscleRatsRats, Sprague-DawleyGlucoseangiotensin IIendothelial cellsfibroblastsglycolysisvascular smooth muscle cells

Identifiers

PMID34817269
PMCPMC8791793
OpenAlexW3217086596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.